320 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-2887
Associate Professor-Clinical, Pathology
Representative to the Department of Medicine for Faculty Mentorship Group.
With the assistance of my collaborator in the Department of Pathology, Dr. Haifeng Wu, we have established and expanded The Ohio State University Thrombotic Thrombocytopenic Purpura (TTP) Research Program dramatically over the past year. Since initiating this research program now 10 years ago, we have enrolled over 80 patients and banked over 3,000 plasma samples for present and future study, not an insignificant accomplishment for such rare disease. Our work has resulted in the publication of over 40 peer-reviewed articles in peer-reviewed journals as well as several abstracts that have been presented in both oral and poster forms at international meetings in the field. We have also patented a novel methodology to measure a laboratory biomarker in TTP and have established Dr. Haifeng Wu’s research lab as a CAP certified, national reference lab for the clinical evaluation of ADAMTS13 biomarkers.
We have completed 2 prospective therapeutic trials evaluating the use of adjuvant immune-suppressive therapy as an adjunct to plasma exchange. These studies have led to a multi-center, prospective randomized trial of corticosteroids or cyclosporine as an adjunct to plasma exchange which we as the lead institution and have opened and have begun accruing patients. This study is presently ongoing and being supported by an R01 from the FDA for which I am the co-principal investigator
Based on the accomplishments of our research program, we previously entered into an agreement with the Archemix Corporation to conduct an observational and retrospective study in TTP, the goal of which is to eventually proceed with a multinational, randomized study of a novel therapy for TTP. I was appointed to the steering committee of this international study and that was closed prematurely, but the initial results of the study were published with myself as the lead author.
Based upon my involvement and leadership in the previously mentioned study, I was asked to be the North American Study Coordinator and consultant to Ablynx for a multicenter, international therapeutic TTP study similarly using an A1 domain targeting therapy. This clinical trial studying a truly novel TTP therapy is presently accruing patients internationally with Ohio State being the lead North American site. I also serve as a consultant for the ongoing management of this study and eventually the analysis and publication of the data when the study is complete.
An additional focus of our work in the Ohio State TTP Research program has centered around study novel laboratory biomarker data to objectively and accurately differentiate TTP from other forms of thrombotic microangiopathies that require a different and unique form of therapy. We have developed a panel of ADAMTS13 and complement activation biomarkers that are being studied regarding their ability to differentiate these disorders as well as predict clinical outcome. We recently received a $200,000 research grant from Alexion to further expand these research efforts in patients with aHUS. Additionally, we just received a $200,000 research grant from the Answering TTP Foundation to expand our efforts to study the role of complement activation in patients acutely presenting with the diagnosis of TTP and throughout long term follow-up.
We expect both the number of publications and the significance of these publications and the influence of our work to continue to increase in the coming years. Our research program is unique in its laboratory and clinical expertise that allows us to conduct basic science and mechanistic studies, but also to enable us to lead international TTP and aHUS studies given our expertise and expansive cohort of patients followed. Increases in research funding more recently will provide the resources required to continue to expand the impact of the Ohio State TTP Research Program. Additional grant proposals supporting our studies of complement activation in patients with thrombotic microangiopathies (TTP and aHUS) have been submitted and favorably scored which will help support the continued growth of our program.
Since joining the faculty in of Ohio State University I have been active in the teaching of medical students, residents, and fellows. I was involved in curriculum development having designed and helped to implement the Hematologic Pathophysiology Independent Study module for the second year Independent Study Program. In addition, I have been a regular lecturer in the college of medicine for both students in the second year of medical school as well as third year students as they go through their internal medicine rotations. I am also very active in the mentoring and clinical teaching of medical students, residents and fellows on in the patient benign hematology consult service as well as in my outpatient clinic. I received the Bertha Bourncle Teaching Award in 2007 which is given recognize the teacher of the year in the Division of Hematology. The reviews and evaluations received from students, fellows, and from peers/audience members from the numerous lectures, invited presentations, and CME presentations I believe support the effectiveness of my teaching skills.
Despite my active research responsibilities, I have maintained an active clinical practice where I see outpatients with benign hematologic diseases 2 days per week. In addition I continue to attend on the inpatient hematology consult service 4 months each year. Administratively, I am an active member of several important committees at the university and the hospital as detailed in my dossier below. I also serve as the director of mentorship for the Division of Hematology and am the mentorship representative to the Department of Medicine from the Division of Hematology. I also have been a member of the Biomedical Sciences Institutional Review Board for the past year and have recently joined the Promotion and Tenure Committee for the Department of Internal Medicine.
|2000 - present||Medical License - 35-06-9289-C: State Medical Board of Ohio|
|2010 - present||Board Certification: American Board of Hematology|
|1997 - 2007||Board Certification: American Board of Internal Medicine|
|2000 - 2010||Board Certification: American Board of Internal Medicine|
|2000 - 2010||Board Certification: American Board of Internal Medicine|
Cataland SR and Larson RA. "Treatment of Adult Acute Lymphoblastic Leukemia." In Clinical Oncology. Edited by Ching Hon Pui Ed, Totowa. 131-141. Columbus, OH: Humana Press, January 2002.
Cataland SR, Shannon K, and Caligiuri MA. "Myelodysplasia." In American Society of Hematology-Self Assessment Program. 200-210. Columbus, OH: Blackwell Publishing, January 2005.
Cataland SR and Weed H. "Hematalogic Issue." In Internal Medicine Care of the Cancer Patient. Edited by People's Medical Publising House, pmph. -. Beijing, CN|CHN: Yeung, SCJ, Escalante C, and Gage, RF eds, October 2007.
Cataland SR and Dean S. "Venous Thromboembolic Disease." In American College of Cardiology Self-Assessment Program. 89 ed. Vol. 6. 716-753. Fort Washington, PA: J Natl Compr Canc Netw, October 2008.
Damodoran S., Cataland SR. "Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time and Platelet Count.." In The Coagulation Consult - A Practical Guide. -.
|12/01/2006||Hematology Consultation Service (James Cancer Hospital, Internal Medicine, Hematology/Oncology)|
|10/01/2009||Associate Professor of Clinical Medicine (2nd floor James Cancer Hospital, Hematology)|
|09/01/2012||Associate Professor of Clinical Medicine (James Care East)|
|07/01/2014||Hematology Out-Patient Clinic (JamesCare East)|
|07/01/2014||Hematology Out-Patient Clinic (2nd Floor James Cancer Hospital Clinic)|
|07/01/2014||In-Patient Hematology Consulatation Service (James Cancer Hospital)|
|01/01/2001 - 09/01/2009||Assistant Professor of Clinical Medicine (2nd floor of the James Cancer Hospital, Hematology/Oncology)|
Cataland,S,R; George,J,N; Kraut,E,H; Bourgeois,T,T; Ferketich,A,K; Kennedy,M,S; Caligiuri,M,A; Wu,H,FM. "Improved clinical outcome and ADAMTS13 activity following cyclosporine therapy in patients with TTP.." In BLOOD. (November 2004). 243A-243A.
Cataland,S,R; Jin,M; Ferketich,A,K; Zheng,X,L; George,J,N; Wu,H,M. "Cyclosporine alone for the treatment of early recurrences of TTP." In BLOOD. (November 2005). 359A-360A.
Cataland,S,R; Jin,M; Ferketich,A,K; Kraut,E,H; George,J,N; Wu,H,M. "Cyclosporine and plasma exchange is superior to corticosteroids and plasma exchange as initial therapy of TTP." In BLOOD. (November 2005). 359A-359A.
Cataland,Spero,R; Jin,Ming; Lin,Shili; Kennedy,Melanie; Kraut,Eric,H; George,James,N; Wu,Haifeng,M. "ADAMTS13 antigen levels and the risk of relapse during long-term clinical follow up of patients with idiopathic thrombotic thrombocytopenic purpura.." In BLOOD. (November 2007). 940A-941A.
Wu,H,M; Cataland,S,R; Kennedy,M,S; Lin,S; Jin,M. "Low ADAMTS13 activity in clinical remission predicts the risk of TTP relapses." In TRANSFUSION. (September 2007). 14A-14A.
Cataland,S,R; Jin,M; Lin,S; Home,A; Kraut,E,H; George,J,N; Wu,H,M. "Cyclosporine is effective prophylactic therapy in preventing recurrences of TTP." In TRANSFUSION. (September 2007). 51A-52A.
Wu,H; Cataland,S. "Clinical utility of ADAMTS13 biomarkers in the evaluation of TTP." In TRANSFUSION. (September 2008). 256A-256A.
Cataland,S,R; Yang,S; Jin,M; Gilbert,J; Wu,H,M. "S100 beta as a Sensitive Biomarker for Acute and Chronic Neurologic Injury in TTP Patients." In TRANSFUSION. (September 2009). 74A-74A.
|1990||B.S., The Ohio State University|
|1994||M.D., The Ohio State University|
|2004 - present||British Journal of Haematology|
|2004 - present||Blood|
|2005 - present||Thrombosis and Hemostasis|
|2005 - present||American Journal of Hematology|
|2008 - present||Nature Clinical Practice Cardiovascular|
|2008 - present||Nature Cardiovascular Medicine|
|1990 - 1991||College of Business Pacesetter Award.|
|1990 - 1991||Summa Cum Laude.|
|1992 - 1993||Cancer Research Assistant Program Grant.|
|1999 - 1998||Amgen Fellow.|
|1999 - 2000||Kaminer Award.|
|2007||Bertha Bouroncle Distinguished Faculty Teaching Award. Division of Hematolgoy/Oncology.|
Cataland, SR, Lucas M, Byrd JC.. "Antibody therapy of acute and chronic leukemias.." Current pharmaceutical biotechnology. Vol. 2, no. 4. (December 2001.): 357-67.
Cataland SR, Daugherty CK, Weseman EC, Larson RA.. "Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia.." Leukemia & lymphoma. Vol. 41, no. 3-4. (December 2001.): 297-307.
Porcu P; Farag S; Marcucci G; Cataland SR; Kennedy MS; Bissell M. "Leukocytoreduction for acute leukemia.." Therapeutic Apheresis: Official Journal Of The International Society For Apheresis And The Japanese Society For Apheresis. Vol. 6, no. 1. (February 2002.): 15-.
Marcucci G; Byrd JC; Dai G; Klisovic MI; Kourlas PJ; Young DC; Cataland SR; Fisher DB; Lucas D; Chan KK; Porcu P; Lin ZP; Farag SF; Frankel SR; Zwiebel JA; Kraut EH; Balcerzak SP; Bloomfield CD; Grever MR; Caligiuri MA. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.." Blood. Vol. 101, no. 2. (January 2003.): 425-.
Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK. "Myeloid growth factors clinical practice guidelines in oncology." J Natl Compr Canc Netw. Vol. 3, no. 4. (July 2005.): 540-55.
Cataland, S.R. & Wu, H.M. "Immunotherapy for thrombotic thrombocytopenic purpura." Curr Opin Hematol. Vol. 5, no. 12. (September 2005.): 359-363.
Wagman,Lawrence,D; Baird,Melissa,F; Bennett,Charles,L; Bockenstedt,Paula,L; Cataland,Spero,R; Fanikos,John; Fogarty,Patrick,F; Goldhaber,Samuel,Z; Grover,Tejpal,S; Haire,William; Hassoun,Hani; Jahanzeb,Mohammad; Leung,Lawrence,L; Linenberger,Michael,L; Millenson,Michael,M; Ortel,Thomas,L; Salem,Riad; Smith,Judy,L; Streiff,Michael,B. "Venous thromboembolic disease. Clinical practice guidelines in oncology.." Journal of the National Comprehensive Cancer Network. Vol. 4, no. 9. (October 2006.): 838-869.
Raman, Subha, V; Simonetti, Orlando, P; Cataland, Spero, R; Kraut, Eric H. "Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease.." Haematologica. Vol. 91, no. 10. (October 2006.): 1329-35.
Cataland, S, R; Jin, M; Smith, E; Stanek, M; Wu, H M. "Full evaluation of an acquired case of thrombotic thrombocytopenic purpura following the surgical resection of glioblastoma multiforme.." Journal of thrombosis and haemostasis : JTH. Vol. 4, no. 12. (December 2006.): 2733-7.
Jin, M; Cataland, S; Bissell, M; Wu, H M. "A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.." Journal of Thrombosis and Haemostasis : JTH. Vol. 4, no. 2. (February 2006.): 333-8.
Wu,Haifeng,M; Cataland,Spero,R; Bissell,Michael; Jin,Ming. "Application of SELDI-TOF mass spectrometry in clinical evaluation of thrombotic thrombocytopenic purpura." SPECTROSCOPY-AN INTERNATIONAL JOURNAL. Vol. 20, no. 5-6. (January 2006.): 219-227.
Cataland, S, R; Jin, M; Zheng, X, L; George, J, N; Wu, H M. "An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura.." Journal of thrombosis and haemostasis : JTH. Vol. 4, no. 5. (May 2006.): 1162-4.
Cataland, Spero, R; Jin, Ming; Wu, Haifeng M. "Rapid determination of ADAMTS13 activity improves clinical decision-making.." American journal of hematology. Vol. 82, no. 3. (January 2007.): 251-.
Cataland, Spero, R; Wu, Haifeng M. "Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.." Expert opinion on pharmacotherapy. Vol. 8, no. 4. (March 2007.): 437-44.
Cataland, Spero, R; Jin, Ming; Ferketich, Amy, K; Kennedy, Melanie, S; Kraut, Eric, H; George, James, N; Wu, Haifeng M. "An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.." British journal of haematology. Vol. 136, no. 1. (October 2007.): 146-9.
Cataland SR, Ming J, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM. "Cyclosporine and Plasma Exchange in TTP: Long-Term Follow-Up with Serial Analysis of ADAMTS13 Activity." Br J Haematol. Vol. 139, no. 3. (November 2007.): 486-93.
Crawford,Jeffrey; Althaus,Betsy; Armitage,James; Balducci,Lodovico; Bennett,Charles; Blayney,Douglas,W; Cataland,Spero,R; Dale,David,C; Demetri,George,D; Erba,Harry,P; Foran,James; Freifeld,Alison,G; Heaney,Mark,L; Htoy,Sally; Kloth,Dwight,D; Lyman,Gary,H; Messersmith,Wells,A; Michaud,Laura,Boehnke; Miyata,Sarah,C; Robbins,Amy; Tallman,Martin,S; Vadhan-Raj,Saroj; Westervelt,Peter; Wong,Michael,K. "Myeloid growth factors. Clinical practice guidelines in oncology.." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 5, no. 2. (February 2007.): 188-202.
Wu H, Cataland S, Michael Bissell, and Jin M. "Application of SELDIâ€“TOF mass spectrometry in Clinical Diagnosis." Spectroscopy. Vol. 20, no. 5/6. (January 2007.): -.
Cataland SR; Jin M; Lin S; Kraut EH; George JN; Wu HM. "Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.." American Journal Of Hematology. Vol. 83, no. 12. (December 2008.): 911-.
Wagman,Lawrence,D; Baird,Melissa,F; Bennett,Charles,L; Bockenstedt,Paula,L; Cataland,Spero,R; Fanikos,John; Fogarty,Patrick,F; Goldhaber,Samuel,Z; Grover,Tejpal,S; Haire,William; Hassoun,Hani; Hutchinson,Suzanne; Jahanzeb,Mohammad; Lee,Jason; Linenberger,Michael,L; Millenson,Michael,M; Ortel,Thomas,L; Salem,Riad; Smith,Judy,L; Streiff,Michael,B; Vedantham,Suresh. "Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology.." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 6, no. 8. (September 2008.): 716-753.
Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. "Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse." Br J Haematol. Vol. 141, no. 5. (May 2008.): 651-8.
Kerlin BA, Cataland S, Varga E, Kraut E, Wurster, M. "Common clinical variables predict warfarin maintenance dose and therapeutic resistance." J Thromb Thrombolysis. Vol. ., (February 2008.): .-.
Klisovic, Rebecca, B; Stock, Wendy; Cataland, Spero; Klisovic, Marko, I; Liu, Shujun; Blum, William; Green, Margaret; Odenike, Olatoyosi; Godley, Lucy; Burgt, Jennifer Vanden; Van Laar, Emily; Cullen, Michael; Macleod, A Robert; Besterman, Jeffrey, M; Reid, Gregory, K; Byrd, John, C; Marcucci, Guido. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.." Clinical cancer research : An Official Journal of the American Association for Cancer Research. Vol. 14, no. 8. (January 2008.): 2444-2449.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK. "Myeloid growth factors.." Journal Of The National Comprehensive Cancer Network: JNCCN. Vol. 7, no. 1. (January 2009.): 64-.
Ntukidem, Nse; Arce lara, Carlos; Otterson, Gregory; Kraut, Eric; Cataland, Spero; Bekaii-Saab, Tanios. "Capped-Dose Mitomycin C (MMC): A Pooled Safety Analysis from Three Prospective Clinical Trials." Cancer Chemotherapy and Pharmacology. Vol. 65, (May 2009.): 319-324.
Cataland SR,Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM. "Demographic and ADAMTS13 Biomarker Data as Predictors of Early Recurrences of Idopathic Thrombotic Thrombocytopenic Purpura." Eur J Haematol. Vol. 83, (August 2009.): 559-564.
Hofmeister CC, Jin M, Cataland SR, Benson DM, Wu HM. "TTP Disease Course is Independent of Myeloma Treatment and Respo." Hematol. Vol. 85, no. 4. (April 2010.): 304-306.
P.M. Wahl, D.R. Terrell, J.N. George, J.K. Rodgers, L. Uhl, S. Cataland,R.L. Bohn. "Validation of Claims-Based Diagnostic Codes for Idiopathic Thrombotic Thrombocytopenic Purpura in a Commercially-Insured Population." Thrombosis and Haemostasis. Vol. 103, no. 6. (January 2010.): 1203-1209.
Viswanathan S, Rovin BH, Shidham GB, Raman SV, Weinberg M, Patricia A, George JN, Wu HM, Cataland, SR. "Long-Term, Sub-Clinical Cardiac and Renal Complications in Patients with Multiple Relapses of Thrombotic Thrombocytopenic Purpura." BR J Haemoatol. Vol. 149, no. 4. (May 2010.): 623-5.
Prescott HC; Wu HM; Cataland SR; Baiocchi RA. "Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome.." American Journal Of Hematology. Vol. 85, no. 12. (December 2010.): 976-.
Wahl PM; Terrell DR; George JN; Rodgers JK; Uhl L; Cataland S; Bohn RL. "Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population.." Thrombosis And Haemostasis. Vol. 103, no. 6. (June 2010.): 1203-.
Zheng XL; Wu HM; Shang D; Falls E; Skipwith CG; Cataland SR; Bennett CL; Kwaan HC. "Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.." Haematologica. Vol. 95, no. 9. (September 2010.): 1555-.
Cataland SR. "3 Rs: rituximab, remission, relapse.." Blood. Vol. 118, no. 7. (August 2011.): 1711-.
Cataland,Spero,R; Wu,Haifeng,M. "Practical Issues in ADAMTS13 Testing and Emerging Therapies in Thrombotic Thrombocytopenic Purpura." SEMINARS IN HEMATOLOGY. Vol. 48, no. 4. (October 2011.): 242-250.
Cataland SR; Scully MA; Paskavitz J; Maruff P; Witkoff L; Jin M; Uva N; Gilbert JC; Wu HM. "Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura.." American Journal Of Hematology. Vol. 86, no. 1. (January 2011.): 87-.
Yang S; Jin M; Lin S; Cataland S; Wu H. "ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome.." Haematologica. Vol. 96, no. 10. (October 2011.): 1521-.
Raman,Rachna; Yang,Shangbin; Wu,Haifeng,M; Cataland,Spero,R. "ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 153, no. 2. (April 2011.): 277-278.
Streiff MB; Bockenstedt PL; Cataland SR; Chesney C; Eby C; Fanikos J; Fogarty PF; Gao S; Garcia-Aguilar J; Goldhaber SZ; Hassoun H; Hendrie P; Holmstrom B; Jones KA; Kuderer N; Lee JT; Millenson MM; Neff AT; Ortel TL; Smith JL; Yee GC; Zakarija A. "Venous thromboembolic disease.." Journal Of The National Comprehensive Cancer Network: JNCCN. Vol. 9, no. 7. (July 2011.): 714-.
Cataland,Spero,R; Yang,Shangbin; Wu,Haifeng,M. "The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 157, no. 4. (May 2012.): 501-503.
Cataland,Spero,R. "Recent advances in the management of atypical hemolytic uremic syndrome.." Clinical advances in hematology & oncology : H&O. Vol. 10, no. 8. (August 2012.): 537-539.
Cataland,Spero,R; Peyvandi,Flora; Mannucci,Pier,M; Lämmle,Bernhard; Kremer Hovinga,Johanna,A; Machin,Samuel,J; Scully,Marie; Rock,Gail; Gilbert,James,C; Yang,Shangbin; Wu,Haifeng; Jilma,Bernd; Knoebl,Paul. "Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.." American journal of hematology. Vol. 87, no. 4. (April 2012.): 430-432.
Salem G, Flynn JM, Cataland SR.. "Profound neurological injury in a patient with atypical hemolytic uremic syndrome.." Ann Hematol.. Vol. 92, no. 4. (April 2013.): 557-8.
Cataland SR and WU HM. "Atypical Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura: Clinically Differentiating the Thrombotic Microangiopathies." European Journal of Internal Medicine. Vol. ., (June 2013.): .-.
Carr, R, Cataland SR. "Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with hHUS and factor H mutation.." Ann Hematol.. Vol. 92, no. 6. (June 2013.): 845-6.
|January 1998||Cataland SR, Kuzel T, Vogelzang NJ, Stadler WM.."A Phase II Trial of Radiation (RT) and Outpatient Subcutaneous IL-2 Plus GM-CSF in Patients with Metastatic Renal Cell Cancer." . : 1262|
|January 1998||Cataland SR, Clementi B, Daugherty, CK, Larson RA.."Preliminary experience with a novel of post-remission chemotherapy regimen for adults with acute lymphoblastic leukemia." . : 255a|
|January 1999||Cataland SR, Weseman E, Daugherty CK, Larson RA."Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia." . : 296a|
|January 1999||Cataland SR, Thirman MJ."Molecular and clinical analysis of MLL-ELL translocations inpatients with acute leukemia." . : 498a|
|January 2004||Cataland SR, George JN, Kraut EH, Bourgeois TT, Ferketich AK, Kennedy MS, Caligiuri MA, Wu HM.."Improved Clinical Outcome and ADAMTS13 Activity Following Cyclosporine Therapy in Patients with TTP" . : 243a|
|November 2004||William Blum, Kristie A. Blum, Cheryl Kefauver, Mollie Moran, Kenneth Chan, John C. Byrd, Spero Cataland, Michael R. Grever, Guido Marcucci."Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report." .|
|November 2005||Wendy Stock, Daohal Yu, Ben Sanford, Gerard Lozanski, Spero Cataland, Ravi Vij, John Byrd, Bayard Powell, Meir Wetzler, Maher Albitar, Dorie Sher, Colin Edwards, Eva Hoke, Clara D. Bloomfield, Richard A. Larson."Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102)" Chicago.|
|November 2005||Subha V. Raman, Orlando P. Simonetti, Spero R. Cataland, William J. Hicks, Eric H. Kraut."Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease." .|
|November 2005||Spero R. Cataland, Ming Jin, Amy K. Ferketich, Eric H. Kraut, James N. George, Haifeng M. Wu.."Cyclosporine and Plasma Exchange is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP" .|
|November 2005||Spero R. Cataland, Min Jin, Amy K. Ferketich, X. Long Zheng, James N. George, Haifeng M. Wu.."Cyclosporine Alone for the Treatment of Early Recurrences of TTP." .|
|November 2005||Kurt P. Leuenberger, Spero Cataland, Ming Jin, Carol Orr, Guido Marcucci, Eric H. Kraut, Haifeng Wu."Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach." .|
|November 2005||Haifeng Wu, Spero Cataland, Michael Bissell, Ming Jin.."A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry." .|
|November 2005||Guido Marcucci, W. Stock, J.A. Zwiebel, S.R. Cataland, G. Dai, M. Moran, D. Lucas, S. Liu, M.I. Klisovic, C. Kefauver, M. Green, K. K. Chan, S. R. Frankel, M.R. Grever, J.C. Byrd."Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in combination with Daunorubicin and Cytarbine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)." .|
|November 2005||Eric H. Kraut, Spero R. Cataland, Leslie Witkoff, Sylvia Jordan, William T. Gunning."Evaluation of Qualitative Platelet Disorders in Patients with Hemophilia" .|
|November 2006||Spero R. Cataland, Eric H. Kraut, Don Benson, Amy K. Ferketich, April Horne, Ming Jin, James N. George, Haifeng M. Wu.."Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP" .|
|January 2007||Cataland SR, Jin, M, Lin S, Kennedy MS, Kraut EH, George JN, and Wu HM.."ADAMTS13 Antigen Levels and the Risk of Relapse During Long-Term Follow-Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura." . : 3204a|
|April 2008||Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G.."A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia." . : 2444|
|May 2008||Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM.."Relationship between ADAMTS 13 activity in clinical remission and the risk of TTP relapse." . : 8|
Haifeng Wu, Ming Jin, Spero Cataland, Michael Bissell. "A diagnosis test for Thrombotic Thrombocytopenia Purpura using SEDLI-TOF Spectrometer.." Filed January 2005.
"Preliminary Experience with a Novel Post-Remission Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia." Presented at Midwest Regional Meeting of the Central Society for Clinical Research, Chicago, IL. (September 1998)
"Advances in Thrombotic Thrombcytopenic Purpura." Presented at ASH Review, Dayton, OH. (January 2002)
"Hematologic Disorders of Pregnancy." Presented at 3rd Annual Dayton Hematology Symposium, Dayton, OH. (October 2005)
"Doctor, Why Am I Bruising So Easily?." Presented at 3rd Annual Dayton Hematology Symposium, Dayton, OH. (October 2005)
"Immune Based Therapy of TTP." Presented at Exciting New Development in Hematology, Columbus, OH. (May 2006)
"Prospective Studies with Long-Term Follow-Up of Corticosteroids and Cyclosporine Given Individually as Adjuncts to Plasma Exchange in the Initial Treatment of TTP." Presented at Plenary Session, American Society for Apheresis Annual Meeting, Nashville, TN. (April 2007)
"Hemostasis and Thrombosis." Presented at (ASH) The American Society of Hematology Review, Columbus, OH. (January 2008)
"Evaluating Coagulopathies." Presented at Dayton Hematology/Oncology Symposium, Dayton, OH. (September 2008)
"Differentiating the Thrombotic Microaniopathies: The Role of ADAMTS13 Activity Testing in TTP." Presented at Dayton Hematology/Oncology Symposium, Dayton, OH. (September 2008)
"Randomized Study of Cyclosporine or Corticostero8ids and Plasma Exhcnage as the Initial Therapy of Thrombotic Thrombocytopenic Purpura." Presented at National Blood Foundation Grant Recipientâ€™s Lecture and Luncheon, Montreal, QC, CA|CAN. (October 2008)
"Venous Thromboembolid Disease and Hypercoagulable Disorders." Presented at The Ohio State University Family Medicine, Columbus, OH. (February 2008)
"Nplate for Chronic Immune Thrombocytopenic Purpura." Presented at Nexus Presentation, Columbus, OH. (November 2009)
"Heparin Induced Thrombocytopenia." Presented at Medical Staff Conference, Newark, OH. (October 2009)
"Objective Documentation of Neurologic Injury in Patients with Idiopathic Thrombotic Thrombocytopenia Pupura (TTP)." Presented at ISTH Congress, Boston, MA. (July 2009)
"ADAMTS13 Activity, Race, and Age as Predictors of Exacerbation in Patients with Idiopathic Thrombotic Thrombocytopenic Purpura (TTP)." Presented at ISTH Congress, Boston, MA. (July 2009)
"ITP." Presented at ASH/ASCO Chapter Meeting, Omaha, NE. (December 2009)
"Hypercoaguable State." Presented at Vascular Surgery Department Presentation, Columbus, OH. (June 2010)
"A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study ofARC1779 in Patients with Thrombotic Thrombocytopenic Purpura (TTP)." Presented at 52nd ASH Annual Meeting and Exposition, Orlando, FL. (December 2010)
"(ITP) Idiopathic Thrombotic Purpura." Presented at Amgen Speaker's Program, Ashland. (October 2010)
"Genetic Testing in Venous Thromboembolic Disease: Does it Really Matter Clinically?." Presented at Ohio 2011 Collaborative Laboratory Conference, Strongsville, OH. (May 2011)
"Evolving Understanding of Atypical Hemolytic Uremic Syndrome.." Presented at Grand Rounds, Chicago, IL. (April 2012)
"Treatment options for TTP and atypical HUS in the 21st century.." Presented at Grand Rounds, Chicago, IL. (June 2012)
"Changing Perspectives on TTP and Atypical HUS." Presented at 2012 ASH Review, Columbus, OH. (December 2012)
"Challenges in Differentiating the Thrombotic Microangiopathies. TTP and aHUS Symposium.." Presented at Grand Rounds, Ann Arbor, MI. (November 2012)
"aHUS and (TTP) Thrombotic Thrombocytopenic Purpura." Presented at 2011 Meeting of the American Society of Hematology Review, Cleveland. (January 2012)
"Thrombotic Thrombocytopenic Purpura." Presented at Basic Science and Clinical Lecture Series, Columbus, OH. (March 2012)
"Advances in Diagnosis and Treatment of aHUS." Presented at ION Solutions American Socity of Hematology Review Meeting 2012, Orlando, FL. (February 2012)
"Diagnosis and Management of Microangiopathic Hemolytic Anemias.." Presented at American Society of Hematology Consultative Hematology Course, Atlanta, GA. (December 2012)
"Complement Medicated Thrombotic Microangiopathies." Presented at Hemostasis and Thrombosis Research Society (HTRS) Scientific Symposium, Charlotte, NC. (April 2013)
"Advances in the Management of Complement-Mediated Thrombotic Microangiopathies.." Presented at Symposium at the 18th Congress of the European Hematology Association, Stockholm, SE|SWE. (June 2013)
|2006 - present||Panel Expert for Net Wellness, Consumer Health Information. Net Wellness, Consumer Health Information. Columbus, OH.|
|2008 - present||National Study Coordinator for Archemix 006 Clinical Trial. Archemix.|
|2008 - present||Invited Member of International Steering Committee. Archemix.|
|2009 - present||Thrombotic Thromboctytopenic Purpura (TTP) Patient Support Group Meeting. Columbus, OH.|
|2010 - present||Expert to the Answering Thrombotic Thrombocytopeni Purpura (TTP) Foundation.|
|2010 - present||Atypical Hemolytic Uremic Syndrome International Advisory Board Meeting. Alexion Pharmaceuticals. Orlando, FL.|